Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of targeted antimicrobial therapy for patients with infections and could potentially extend the lifespan of current narrow-spectrum antimicrobials. Although conceptually new and rapid AST technologies have been described, including new phenotyping methods, digital imaging and genomic approaches, there is no single major, or broadly accepted, technological breakthrough that leads the field of rapid AST platform development. This might be owing to several barriers that prevent the timely development and implementation of novel and rapid AST platforms in health-care settings. In this Consensus Statement, we explore such barriers, which include the utility of new methods, the complex process of validating new technology against reference methods beyond the proof-of-concept phase, the legal and regulatory landscapes, costs, the uptake of new tools, reagent stability, optimization of target product profiles, difficulties conducting clinical trials and issues relating to quality and quality control, and present possible solutions.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41579-018-0098-9, hdl.handle.net/1765/111533
Journal Nature Reviews Microbiology
Citation
van Belkum, A.F, Bachmann, T.T. (Till T.), Lüdke, G. (Gerd), Lisby, J.G. (Jan Gorm), Kahlmeter, G, Mohess, A. (Allan), … Dunne, W.M. (2018). Developmental roadmap for antimicrobial susceptibility testing systems. Nature Reviews Microbiology. doi:10.1038/s41579-018-0098-9